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Abstract 
Background: Non‑alcoholic steatohepatitis (NASH) is an obesity associated common cause of liver inflammation 
and there are concerns that it may turn out to be the most common cause of liver failure as prevalence of obesity 
increases. We determined the prevalence of NASH in relation to gender and body mass index (BMI). Furthermore, we 
assessed the association of NASH with the length of the small bowel.
Methods: 124 liver samples obtained during routine operations were examined looking for NAFLD Activity Score 
(nonalcoholic fatty liver disease). The length of small bowel was measured intraoperatively. For evaluation, patients 
were divided into four groups according to their BMI (group 1: normal weight, group 2: overweight, group 3: grade I/II 
morbidly obese, and group 4 grade III morbidly obese patients).
Results: BMI showed a strong positive correlation with risk of NASH and a weak positive correlation with small bowel 
length. No normal weight patient was at risk of NASH, whereas in group 2 14% had uncertain and 32% definite NASH. 
In group 3 11% had uncertain and 27% definite NASH. In group 4 nearly two‑thirds were classified as uncertain or 
definite NASH. Median length of small bowel in all patients was 450 cm (range 226–860 cm). Within group 4, patients 
with definite/uncertain NASH had a longer small bowel than patients without NASH.
Conclusions: Prevalence of NASH is high in morbidly obese. Small bowel length could influence the complex etiol‑
ogy of the disease.
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Background
Non-alcoholic fatty liver disease (NAFLD), defined by 
non-alcohol related excessive fat accumulation in the 
liver, is a leading cause of chronic liver disease worldwide. 
Obesity is a major risk factor for NAFLD and NAFLD 
is often linked to other obesity related diseases such as 
insulin resistance and several features of metabolic syn-
drome. Although simple steatosis carries a relatively 
benign prognosis, a significant proportion of patients will 
progress to non-alcoholic steatohepatitis (NASH) [1]. 
NASH is the advanced form of NAFLD, leading to liver 
cirrhosis, end-stage liver disease, and hepatocellular car-
cinoma [2]. As the worldwide obesity epidemic continues 
to increase, NASH will surpass chronic hepatitis C infec-
tion as the primary indication for orthotopic liver trans-
plantation [3]. Although the pathogenesis of NAFLD/
NASH is not yet fully understood, excess intracellular 
fatty acids, oxidative stress, inflammatory cytokines/
adipocytokines, and mitochondrial dysfunction in 
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association with a genetic predisposition seem to con-
tribute to progression from steatosis to more advanced 
liver inflammation and fibrosis [4]. Insulin resistance also 
is reported to be a risk factor for the presence of NASH, 
irrespective of obesity [5].
Histologically, the presence of a few steatotic hepato-
cytes in the liver is considered to be normal. The defin-
ing threshold for NALFD is an involvement of more than 
5–10% of the liver. Steatosis of hepatocytes in NAFLD 
typically affects perivenular regions of the liver. In 
NASH, steatosis is accompanied by intralobular inflam-
mation and hepatocyte injury, usually in the form of bal-
looning. Ongoing hepatic damage in NASH can lead to 
fibrosis and cirrhosis in some cases [6]. However, which 
conditions drive the progress of NAFLD towards NASH 
is not yet fully understood. As liver biopsy is mandatory 
for diagnosis of NASH, larger epidemiologic studies are 
challenging.
In this retrospective study, we analyzed 136 liver sam-
ples obtained from patients operated upon in our surgical 
department and determined the prevalence of NASH in 
relation to gender and body mass index (BMI). Further-
more, we assessed the association of NASH with fasting 
insulin levels, hepatic transaminases as well as the length 
of the small bowel measured intraoperatively.
Methods
Patients
Liver samples were obtained from 136 patients (69 males; 
67 females) operated upon in the Department of Gen-
eral and Visceral Surgery at the University Hospital Ulm 
between 2003 and 2007. The study was performed with 
the permission of the independent local ethics committee 
of the University of Ulm (approval 73/2009). A written 
consent was obtained from patients prior to inclusion in 
this study. Patients with a history of alcohol abuse [more 
than 40 g (males)/20 g (females) per day] were excluded. 
12 out of these 136 patients were excluded since a non-
NASH liver disease was diagnosed (e.g., mainly intrahe-
patic cholestasis followed by liver metastasis and viral 
hepatitis/biliary cirrhosis). As shown in Table  1, out of 
the 124 remaining patients (100%), 71 patients (57%) 
were operated upon for malignant disease, mainly colo-
rectal carcinoma, 19 patients (15%) for benign disease, 
mainly pancreatitis and diverticulitis of sigmoid colon, 
and 34 patients (27%) received a bariatric procedure. 61 
patients were females (49%) and 63 patients were males 
(51%). 65% of male patients suffered from a malignant 
disease (mostly colorectal carcinoma, followed by pan-
creatic carcinoma and esophageal/gastric cancer). On 
19% of the male patients a bariatric procedure was per-
formed, and 16% of male patients were operated on for 
benign disease, predominantly benign pancreatic disease 
followed by benign small or large bowel disease. 49% of 
female patients were operated on for malignant disease 
(mostly colorectal carcinoma followed by pancreatic 
carcinoma and esophageal/gastric cancer. 36% of female 
patients underwent a bariatric procedure and 15% of 
female patients were operated on for benign disease, pre-
dominantly benign changes of the large bowel followed 
by a benign pancreatic tumor.
Patients were between 21 and 90 years old (median of 
all patients 59  years; female patients 23–86  years, with 
a median of 55 years; male patients 21–90 years, with a 
median of 62 years). Liver samples were taken from the 
left liver lobe, and shock frozen in liquid nitrogen or fixed 
in formalin. Serum levels of alanine transaminase (ALT) 
and fasting insulin were obtained. The length of small 
bowel was accurately measured intraoperatively from the 
ligament of Treitz to the ileocecal junction strictly on the 
mesenteric edge.
For evaluation, patients were divided into four groups 
according to their BMI (Table 1). Normal weight patients 
represent group 1, overweight patients constitute group 
2, grade I/II morbidly obese patients are in group 3, and 
grade III morbidly obese patients are in group 4. Patients 
in group 4 were mainly operated upon for morbid obe-
sity (31 out of 34 patients in this group). Patients oper-
ated upon for benign diseases had similar BMI values 
compared to patients operated on for malignant diseases 
(median 27.5 kg/m2; range 17.6–38.0 vs. median 26.1 kg/
m2; range 18.9–42).
Table 1 Classification of patients according to their BMI (group 1: normal weight; group 2: overweight; group 3: I/II° obe-
sity; group 4: III° obesity)
Group BMI (kg/m2) Malignant disease Benign disease Morbid obesity
All patients (n = 124; ♀61, ♂63) n = 71; ♀30, ♂41 n = 19; ♀9, ♂10 n = 34; ♀22, ♂12
1 (n = 32; ♀12, ♂20) 18.5–24.9 n = 25; ♀10, ♂15 n = 7; ♀2, ♂5 n = 0; ♀0, ♂0
2 (n = 36; ♀13, ♂23) 25.0–29.9 n = 30; ♀11, ♂19 n = 6; ♀2, ♂4 n = 0; ♀0, ♂0
3 (n = 22; ♀12, ♂10) 30.0–39.9 n = 14; ♀7, ♂7 n = 6; ♀5, ♂1 n = 2; ♀0, ♂2
4 (n = 34; ♀24, ♂10) ≤40 n = 2; ♀2, ♂0 n = 0; ♀0, ♂0 n = 32; ♀22, ♂10
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Blood samples were taken 1 day prior to operation in a 
fasting state at 8 am. The study was approved by the local 
ethics committee (study number 112/2003).
Histological staining
After macroscopic assessment (size, color, consistency), 
the resected liver specimens were fixated in 10% neutral 
buffered formalin for 12 h and subsequently dehydrated 
by passing the tissue through a series of increasing alco-
hol concentrations. After dehydration, the tissues were 
embedded in paraffin and trimmed to 3  µm sections. 
After deparaffinization and rehydration with decreasing 
strengths of alcohol, sections were stained with Mayer’s 
hematoxylin (Chroma, Münster) for 15 min, then washed 
in running tap water for 20  min followed by counter-
staining with eosin (Chroma, Münster). After dehydra-
tion in 95% and absolute alcohols, sections were cleared 
in xylene (Merck, Darmstadt) and mounted in Permount 
(Thermo Fisher Scientific Inc).
NAFLD Activity Score (NAS)
Sections were analyzed at 200× magnification with the 
semi-quantitative scoring system according to Kleiner 
et  al. [7]. Table  2 by an expert hepato-pathologist. The 
NAFLD Activity Score (0–8 points) is the sum of scoring 
for steatosis (0–3 points), inflammation (0–3 points) and 
ballooning (0–2 points). A score of at least 5 is defined as 
NASH.
Statistical analysis
All values were expressed as arithmetic mean, standard 
deviation, median, and range. Statistical analysis was 
performed using Winstat software for windows (R. Fitch 
Software Version 2009.1). Data were statistically analyzed 
using the Kruskal–Wallis test (KW) for differences within 
the collective. If significant differences were found, gen-
der-specific analysis was performed (KW test). To test 
differences between two groups, the Mann–Whitney U 
test (MWU) was used. Statistical significance was tested 
at p  <  0.05. Boxplots were chosen to present results, 
whereby top and bottom of the rectangle represent the 
25th and 75th percentile and the line within the rectangle 
represents the median. The whiskers extend from the 5th 
percentile to the 95th percentile. Outliners are marked 
with a circle. Correlations between the different sub-
groups were statistically analyzed using non-parametric 
Spearman’s correlation test, whereby correlation coef-
ficients are indicated by r. Correlation coefficient values 
between 0.3 and 0.7 (−0.3 and −0.7) indicate a moder-
ate, values between 0.7 and 1.0 (−0.7 and −1.0) indicate 
a strong positive (negative) linear relationship. Statisti-
cal significance was tested at p < 0.05 and a tendency at 
0.05 < p < 0.10. No adjustments were made for multiple 
statistical comparisons.
Results
Liver and steatosis in the BMI groups
Steatosis was estimated by histology after stain-
ing. Median fat content of all patients was 4% (female 
patients: median 4%, range 0–90%; male patients: median 
2%, range 0–80%). Overall, 76 patients (61%) had no or 
low grade fatty degeneration of the liver (<5%), grade 1 
liver steatosis (5–33%) was found in 29 patients (23%), 
grade 2 liver steatosis (34–66%) in 12 patients (10%), 
grade 3 liver steatosis (>66%) in 7 patients (6%). As 
showed in Figure  1, group 1 patients had a median fat 
Table 2 NAFLD activity scoring system according to Kleiner et al
NAFLD Activity Score (NAS) (0–8)
 Sum of scores for steatosis, lobular inflammation and hepatocellular ballooning
 ≥5 probable or definite NASH
 3–4 uncertain NASH
 ≤2 no NASH
Steatosis (0–3) Lobular inflammation (0–3) Hepatocyte ballooning (0–2)
 0: 5% hepatocytes involved  0: none  0: none
 1: 5–33% of hepatocytes involved  1: <2 foci per × 200 field  1: few ballooned cells
 2: 33–66% hepatocytes involved  2: 2–4 foci per × 200 field  2: many cells/prominent balloon‑
ing
 3: >66% hepatocytes involved  3: >4 foci per × 200 field
Correlation between total NAFLD activity scores and an overall histological diagnosis of steatohepatitis
 NAFLD activity score and histological diagnosis of steatohepatitis
 ≥5 probable or definite NASH
 3–4 uncertain NASH
 ≤2 no NASH
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content of 1% (range 0–20%), group 2 patients of 3% 
(range 0–30%), group 3 patients of 10% (range 0–60%), 
and group 4 patients of 30% (range 1–90%). There was no 
gender-specific difference in fat content of the liver. As 
expected, BMI showed a strong positive correlation with 
fat content of the liver (correlation coefficient r =  0.70; 
p < 0.01).
Lobular inflammation in the BMI groups
Lobular inflammation was scored by determining the 
number of foci of lobular inflammation per × 200 field. 
Inflammatory foci are aggregates of a mixed population 
of leukocytes usually containing a significant number of 
neutrophils. No lobular inflammation was detectable in 
82 out of 124 patients (66%). 31 patients showed <2 foci 
of lobular inflammation per ×  200 field (25%), whereas 
11 patients showed a lobular inflammation between 2 
and 4 foci (9%). The highest inflammation score, i.e., 
>4 foci of lobular inflammation per × 200 field was not 
observed in any patient. Overall, lobular inflammation 
tended to increase with BMI, as shown by the percentage 
of patients exhibiting detectable inflammation (group 1: 
9%; group 2: 33%; group 3: 36%; group 4: 56%; Figure 2).
Hepatocyte ballooning in the BMI groups
Ballooned liver cells are markedly enlarged and display 
a rounded shape with a weakly stained, reticulated cyto-
plasm. Hepatocyte ballooning is the result of severe cell 
injury, finally leading to cell death. Overall 24 out 124 
patients (19%) had signs of hepatocyte ballooning (Fig-
ure 3). No hepatocyte ballooning was detected in group 
1 patients. 14% of group 2 and group 3 patients had few 
ballooned cells. No patient in group 2 and group 3 had 
many or prominent ballooned cells. In group 4, 1 patient 
(3%) had many/prominent ballooned cells and 14 patients 
(41%) few ballooned cells.
NAFLD Activity Score (NAS)
According to the scoring system by Kleiner et al. [6], 12 
patients (10%) had probable or definite NASH while a 
further 20 patients (16%) had uncertain NASH (Figure 4). 
In group 1, no patient was at risk of NASH, in groups 2 
and 3, 1 patient each (3 and 5%, respectively) had prob-
able or definite NASH and a further 4 and 6 patients, 
respectively (11 and 27%) had uncertain NASH. In group 
4, 10 patients (29%) were classified as uncertain NASH 
and a further 10 (29%) as definite NASH. In this group, 
40% (4 out of 10) of male patients and 42% (10 out of 24) 
of female patients had no NASH. With regard to gender, 
50% of males in group 4 (5 out of 10) were classified as 
uncertain and 10% (1 out of 10) were classified as prob-
able or definite NASH, while 21% (5 out of 24) of group 
4 females had uncertain NASH and 38% (9 out of 24) 
definite NASH. Group 4 patients classified as probable or 
definite NASH had a similar BMI compared to no NASH 
group 4 patients (median 52.8 kg/m2, range 40.8–66.5 kg/
m2 vs. median 54.3 kg/m2, range 35.0–66.4 kg/m2). Fig-
ure 5 shows HE staining of two liver samples.
Figure 1 Hepatic steatosis in the four BMI groups (group 1: BMI 18.5–24.9 kg/m2, group 2: 25.0–29.9 kg/m2, group 3: 30.0–39.9 kg/m2 and group 
4: ≥40 kg/m2) was determined with H&E staining. Steatosis was evaluated semi‑quantitatively described by Kleiner et al. [7]. No steatosis: 0–5% of 
parenchymal involvement by steatosis, first degree steatosis: 5–33% of parenchymal involvement by steatosis, second degree steatosis: 33–66% of 
parenchymal involvement by steatosis, and third degree steatosis: >66% of parenchymal involvement by steatosis.
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Small bowel length, insulin levels, triglycerides, 
and transaminases
Intraoperative small bowel length measurement was doc-
umented in 108 patients. As shown in Table  3, median 
length of small bowel in all patients was 450  cm (range 
226–860  cm) and small bowel length showed a weak 
positive correlation with BMI (r =  0.30; Kruskal–Wallis 
test for different small bowel length between the four 
BMI subgroups: p  <  0.01). Patients with definite/uncer-
tain NASH had a longer small bowel than patients with-
out NASH (p < 0.01). The small bowel of group 4 patients 
was significant longer than of patients in groups 1–3 
(p < 0.01). Within group 4, patients with definite/uncer-
tain NASH had a significantly longer small bowel than 
Figure 2 Intrahepatic lobular inflammation was determined in the four BMI groups (group 1: BMI 18.5–24.9 kg/m2, group 2: 25.0–29.9 kg/m2, group 
3: 30.0–39.9 kg/m2 and group 4: ≥40 kg/m2) with H&E staining (number of foci of lobular inflammation per × 200 field). No lobular inflamma‑
tion was detectable in 81 out of 123 patients (65.9%), 31 patients showed <2 foci of lobular inflammation per × 200 field (25.2%), and 11 patients 
showed between 2 and 4 foci (8.9%). No patient had more than 4 foci of lobular inflammation per × 200 field.
Figure 3 Hepatocyte ballooning was determined with H&E staining in the four BMI groups (group 1: BMI 18.5–24.9 kg/m2, group 2: 25.0–29.9 kg/
m2, group 3: 30.0–39.9 kg/m2 and group 4: ≥40 kg/m2). No hepatocyte ballooning was seen in 100 out of 124 patients (81%) and in all 32 group 
1 patients. 14% each of group 2 and 3 patients had a few ballooned cells. One patient of group 4 had many/prominent ballooned cells and 14 
patients (41%) a few ballooned cells.
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group 4 patients without NASH (p = 0.04). Group 2 and 
3 patients with definite/uncertain NASH did not have a 
significantly longer small bowel than group 2/3 patients 
without NASH (p = 0.24).
We analyzed fasting insulin levels in 31 group 4 
patients. Patients with definite/uncertain NASH had 
higher (not significant) insulin levels (median 31.4 mU/l; 
range 8.9–47.3 mU/l; normal range 2.6–24.9 mU/l) than 
group 4 patients without NASH (median 19.8  mU/l; 
range 4.8–40.0  mU/l; p  =  0.065). Group 2/3 patients 
(definite/uncertain NASH vs. no NASH) showed no dif-
ference in fasting insulin levels (data not shown). We also 
measured triglyceride (TG) levels, because macrovesicu-
lar steatosis occurs as a manifestation of excessive TG 
accumulation in the liver. We found a weak positive cor-
relation between TG levels and BMI (r = 0.26), but within 
a BMI group, patients with definite/uncertain NASH had 
only slightly and not significantly higher TG levels than 
Figure 4 NAFLD Activity Score according to the scoring system of Kleiner et al. 12 patients (10%) had probable or definite NASH and a further 
20 patients (16%) had uncertain NASH. In group 1, no patient was at risk of NASH, in groups 2 and 3, 1 patient each (3% and 5%, respectively) had 
probable or definite NASH and a further 4 and 6 patients (11% and 27%, respectively) had uncertain NASH. In group 4, 10 patients (29%) were classi‑
fied as uncertain NASH and a further 10 (29%) as definite NASH.
Figure 5 HE staining of liver samples (magnification 150×). a Liver tissue of a 49 years old patient operated for malignant disease (BMI 28.4 kg/m2) 
with a low grade fatty degeneration of the liver (<5%) and no lobular inflammation or hepatocyte ballooning. b Liver tissue of a 52 years old patient 
operated for morbid obesity (BMI 60.0 kg/m2) with grade 2 liver steatosis (40%) and some lobular inflammation and hepatocyte ballooning (top 
right an enlarged view; magnification 600×).
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patients without NASH (group 3: median TG levels in 
patients without NASH: 138  mg/dl; range 52–364  mg/
dl, median TG levels in patients with definite/uncertain 
NASH: 170 mg/dl; range 99–272 mg/dl, p = 0.78; group 
4: median 111  mg/dl; range 83–210  mg/dl vs. median 
148 mg/dl; range 71–223 mg/dl, p = 0.16).
Regarding hepatic enzymes, we found a moderate posi-
tive correlation between ALT levels and BMI (r = 0.34). 
Patients with definite/uncertain NASH had significantly 
higher ALT levels (median 50.5 U/l; range 16.0–116.0 U/l; 
normal range: male <45 U/l, female <35 U/l) than patients 
without NASH (median 25.5  U/l; range 12.0–433.0  U/l; 
p < 0.01). Within a BMI group, we found different results 
in BMI groups 3 and 4 patients. BMI group 3 patients 
with definite/uncertain NASH had only slightly, but not 
significantly, higher ALT levels than patients without 
NASH (median ALT levels in patients without NASH: 
28 U/l; range 13–433 U/l, median ALT levels in patients 
with definite/uncertain NASH: 76 U/l; range 18–116 U/l, 
p  =  0.07) while BMI group 4 patients with definite/
uncertain NASH had significantly higher ALT levels than 
BMI group 4 patients without NASH (median ALT lev-
els in patients without NASH: 28  U/l; range 14–38  U/l; 
median ALT levels in patients with definite/uncertain 
NASH: 46 U/l; range 20–114 U/l, p < 0.01).
Discussion
As the worldwide obesity pandemic grows, rates of meta-
bolic syndrome and its hepatic manifestation, NAFLD, 
rise as well. The true prevalence of NAFLD and NASH is 
unknown and disease definition and modalities used for 
diagnosis and epidemiology studies are not standardized 
[8]. Based on imaging studies, the prevalence of NAFLD 
in adult populations ranges between 14 and 31% and in 
the obese, incidence of steatosis increases [9]. In obese 
individuals (BMI > 30 kg/m2), evidence of liver steatosis 
was found in up to 91% on ultrasound [10]. These results 
are comparable with our analysis with a prevalence of 
70% steatosis in obese patients. Hepatic steatosis with-
out NASH is a benign condition that does not impair 
liver function or lead to organ damage [11]. However, 
when hepatic cell necrosis and inflammation appear, fatty 
liver disease can progress into NASH and ultimately lead 
to cirrhosis, end-stage liver disease and hepatocellular 
carcinoma.
Data on prevalence of NASH are more difficult to 
assess than of simple steatosis, since a liver biopsy would 
be required to reliably diagnose NASH. NASH is esti-
mated to occur in about 2–3% of the general popula-
tion while it is found in 25–36% in the morbidly obese 
[10, 12]. We analyzed the prevalence of NASH in 124 
patients, subdivided into four different groups depending 
on patient BMI. We did not find NASH in normal weight 
patients (BMI  <  25  kg/m2). In 36 overweight patients 
(BMI 25 to <30 kg/m2) one patient was staged as prob-
able or definite NASH, and four patients were staged as 
uncertain NASH according to the NASH scoring system 
by Kleiner et al. [7]. With increasing body weight, there 
is an increased prevalence of NASH: 6 out of 22 patients 
with first or second degree obesity (BMI 30 to <40  kg/
m2) and 20 out of 34 patients with third degree obesity 
(BMI ≥ 40 kg/m2) were staged as uncertain NASH or as 
probable or definite NASH. Gender seems to matter in 
that male patients display greater tendency to NASH than 
female patients [13]. In this study, we found no gender-
specific difference in prevalence of NASH. However one 
should remember that patients in group 4 (BMI > 40 kg/
m2) were almost 20 years younger than patients in groups 
1–3. Since NAFLD and NASH are commonly diagnosed 
in morbidly obese patients, a liver biopsy is now recom-
mended in bariatric surgery [14].
The hypothesis that the length of the small intestine 
is related to obesity has been under discussion for a 
long time. Medical literature contains limited and often 
incomprehensible information regarding small bowel 
length in living patients. Average length is mostly given 
as between 280  cm and approximately 600  cm (ranges 
from 260 to 800  cm) [15–17], but average length can 
vary up to almost 10 m [18]. The method employed for 
measurement and the conditions under which the meas-
urements were made could explain the different results 
(autopsy studies, double balloon endoscopy, swallowed 
polyvinyl tube, intraoperative measurement, and here 
measurement along the mesenteric/antimesenteric bor-
der and open/laparoscopic approach). Additionally, 
there are conflicting data regarding small bowel length 
and its relationship to height and weight. While exist-
ing data confirm a relationship between body weight and 
length of small bowel [19], Nassif et  al. found no rela-
tionship in overweight patients submitted to bariatric 
Table 3 Small bowel length
Median (cm) Range (cm)
All patients 450 226–860
Patients without NASH 440 (226–770)
Patients with definite/uncertain NASH 520 (240–860)
Groups 1–3 patients 430 (226–860)
Group 4 patients 495 (312–760)
Group 2/3 patients without NASH 430 226–630
Group 2/3 patients with definite/uncertain 
NASH
455 240–860
Group 4 patients without NASH 555 312–760
Group 4 patients with definite/uncertain 
NASH
480 360–520
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surgery [20]. Remarkably, we found a positive correlation 
between small bowel length and patient BMI. Further-
more, the small bowel of NASH patients was significantly 
longer than the small bowel of patients without NASH. 
It is problematic that a total of six different surgeons 
measured the small bowel intraoperatively, since differ-
ent applied degrees of tension could modify the results. 
Small bowel measurement and bariatric procedures for 
all patients with morbid obesity (in group 4: 32 out of 34 
patients) were conducted by one surgeon only. All proce-
dures were executed in an open approach. The outcomes 
of future research may determine whether bariatric sur-
gery will be one option for treatment of the most pro-
gressive type of NAFLD [21].
Consistent with other studies, we found ALT levels 
were related to advanced liver disease [22, 23], how-
ever only in BMI group 4 patients. BMI group 3 patients 
with and without NASH showed no significant differ-
ence in ALT levels. However, we found no significantly 
higher TG levels in NASH patients than patients with-
out NASH within the same BMI group. Insulin resist-
ance is believed to be a central mechanism involved in 
the development of hepatic steatosis. We found higher 
fasting insulin levels in obese patients (BMI > 30 kg/m2) 
with definite/uncertain NASH than in morbidly obese 
patients (BMI  >  40  kg/m2) without NASH. However 
we found no difference in fasting insulin levels in over-
weight and morbidly obese patients with a BMI below 
40  kg/m2. Current therapy for NASH has focused on 
improving insulin resistance and mediators of inflam-
mation, factors probably associated with disease pro-
gression. Insulin resistance can be targeted through a 
multifaceted approach involving weight loss, surgical 
intervention, or pharmacological therapy [8]. In the 
morbidly obese, the weight loss approach with the most 
durable effect on obesity and NASH is bariatric surgery, 
which can achieve, in particular with a malabsorptive 
procedure, an improvement of NAFLD both biochemi-
cally and histologically [24].
Our study has several strengths and limitations. All 
patients were recruited and operated on in the same 
hospital. Blood samples of all groups were collected 
via the same protocol, simultaneously stored, and pro-
cessed with the same assay. The main limitation of our 
study is its cross-sectional design, so we cannot con-
clude that clinical markers predict progression of liver 
disease, as this would imply examining these compo-
nents prospectively in the same individuals. Further 
limitations relate to the fact that many group 4 patients 
underwent medical weight loss strategies prior to pre-
senting for surgery and the prevalence of medications 
known to impact NASH and metabolism could not be 
accounted for.
Conclusion
Simple steatosis of the liver is highly prevalent especially 
in the obese. In our study, we found steatosis of the liver 
in more than 80% of morbidly obese patients, however, 
probable/definite NASH was found in only 30% of these 
patients (and a further 30% of these patients were clas-
sified as uncertain NASH). The exact pathogenesis and 
natural history are still being defined. Therapy currently 
addresses the features of metabolic syndrome, including 
diabetes, obesity, and dyslipidemia, however, if a connec-
tion between NASH and small bowel length is confirmed, 
malabsorptive bariatric surgery should be considered as a 
further option.
Endnote
This work is dedicated to the memory of Dr. Cornelia 
Schwab, who died on May 07, 2011.
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